KINASE INHIBITORS

FIELD: pharmacology.SUBSTANCE: invention relates to the compound, which is selected from the group consisting of: 1-{3-tert-Butyl-1'-[2-(4-hydroxy-piperidin-1-yl)-ethyl]-1'H-[1,4']bipyrazolyl-5-yl}-3-{4-[3-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalin-1-yl}-urea formiate; 1-(3-tert-Butyl-1'-{2-[(2-methoxy-ethyl)-methyl-amino]-ethyl}-1'H-[1,4']bipyrazolyl-5-yl)-3-{4-[3-(2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalin-1-yl}-urea; 1-[3-tert-Butyl-1'-(2-dimethylamino-ethyl)-1'H-[1,4']bipyrazolyl-5-yl]-3-[4-(3-dimethylamino-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalin-1-yl]-urea formiate; 1-[3-tert-Butyl-1'-(2-dimethylamino-ethyl)-1'H-[1,4']bipyrazolyl-5-yl]-3-{4-[3-(2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalin-1-yl}-urea formiate; 1-[3-tert-Butyl-1'-(3-dimethylamino-propyl)-1'H-[1,4']bipyrazolyl-5-yl]-3-{4-[3-(2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydro-naphthalin-1-yl}-urea formiate; the other compounds are indicated in the formula of invention. The invention also relates to the pharmaceutical composition, to the method of disease or conditions treatment in human, which has a positive result from the inhibition of the p38 MAP kinase activity and to the compound application in the manufacture of the medicinal agent.EFFECT: new compounds are obtained, which have the inhibitory action in regard to the p38 mitogen-activated protein kinase activity.11 cl, 30 ex Изобретение относится к соединению, выбранному из группы, состоящей из: 1-{3-трет-Бутил-1'-[2-(4-гидрокси-пиперидин-1-ил)-этил]-1'H-[1,4']бипиразолил-5-ил}-3-{4-[3-2-метил-пиперидин-1-ил)-[1,2,4]триазоло[4,3-a]пиридин-6-илокси]-1,2,3,4-тетрагидро-нафталин-1-ил}-мочевины формиата; 1-(3-трет-Бутил-1'-{2-[(2-метокси-этил)-метил-амино]-этил}-1'H-[1,4']бипиразолил-5-ил)-3-{4-[3-(2-метил-пиперидин-1-ил)-[1,2,4]триазоло[4,3-a]пиридин-6-илокси]-1,2,3,4-тетрагидро-нафталин-1-ил}-мочевины; 1-[3-трет-Бутил-1'-(2-диметиламино-этил)-1'H-[1,4']бипиразолил-5-ил]-3-[4-(3-диметиламино-[1,2,4]триазоло[4,3-a]пиридин-6-илокси)-1,2,3,4-тетрагидро-нафталин-1-ил]-мочевины формиата; 1-[3-трет-Бутил-1'-(2-диметиламино-этил)-1'H-[1,4']бипиразолил-5-ил]-3-{4-[3-(2-метил-пиперидин-1-ил)-[1,2,4]триазоло[4,3-a]пиридин-6-илокси]-1,2,3,4-тетрагидро-нафталин-1-ил}-мочевины формиата; 1-[3-трет-Бутил-1'-(3-диметиламино-пропил)-1'H-[1,4'